Pediatric Nephrology

, Volume 33, Issue 12, pp 2311–2320 | Cite as

Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study

  • Kelly R. McMahon
  • Maya Harel-Sterling
  • Michael Pizzi
  • Louis Huynh
  • Erin Hessey
  • Michael ZappitelliEmail author
Original Article



Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h ambulatory BP monitoring (ABPM) in this population. We aimed to describe chemotherapy-associated acute kidney injury (AKI) and late kidney outcomes using standardized definitions.


This was a single-center longitudinal pilot study of 23 children who participated in a previous study during cisplatin, carboplatin, or ifosfamide treatment. Medical charts were reviewed retrospectively. Available patients were approached for a study visit for blood and urine collection, BP measurement, and ABPM. AKI is defined by serum creatinine (SCr) rise (Kidney Disease: Improving Global Outcomes definition [SCr-AKI]). Electrolyte-AKI is defined by hypokalemia, hypophosphatemia, or hypomagnesemia. Chronic kidney disease (CKD) is defined by estimated glomerular filtration rate < 90 mL/min/1.73 m2, albuminuria, or proteinuria. Electrolyte-CKD is defined by low serum electrolyte concentration or electrolyte supplementation.


Median age at chemotherapy start was 8.3 years; 9/23 (39%) were boys. Fourteen out of 23 (61%) patients had SCr-AKI during therapy; all developed electrolyte-AKI. Median 5.7 years post-chemotherapy, 7/22 (32%) had CKD, 11/23 (48%) had electrolyte-CKD, and 2/20 (10%) had hypertension. Fifteen out of 23 patients (65%) had either CKD, electrolyte-CKD, or hypertension. In ten patients available for a study visit (median 4.9 years post-chemotherapy), 1/10 (10%) had hypertension by ABPM; none had masked or white coat hypertension. All ten had at least one kidney abnormality (CKD, electrolyte-CKD, office pre-hypertension, or abnormal ABPM).


Using standardized outcome definitions, children treated with cisplatin, carboplatin, or ifosfamide have a high prevalence of late kidney abnormalities. Research must elucidate best practice for post-cancer treatment follow-up and kidney complication treatment.


Chemotherapy Pediatric Acute kidney injury Chronic kidney disease Hypertension 



We would like to acknowledge the work performed by all study staff for specimen and data collection. A special thank you goes to study participants and their families.


This work was supported by grants from the Fonds de recherche du Québec - Santé (FRQS) and the Kidney Research Scientist Core Education and National Training Program (KRESCENT) awarded to Michael Zappitelli. A FRQS Doctoral Training Scholarship awarded to Kelly McMahon also helped support this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For the retrospective study component, formal consent was not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

467_2018_3976_MOESM1_ESM.docx (19 kb)
ESM 1 (DOCX 18 kb)
467_2018_3976_MOESM2_ESM.docx (16 kb)
ESM 2 (DOCX 16 kb)
467_2018_3976_MOESM3_ESM.docx (17 kb)
ESM 3 (DOCX 16 kb)
467_2018_3976_MOESM4_ESM.docx (16 kb)
ESM 4 (DOCX 16 kb)
467_2018_3976_MOESM5_ESM.docx (16 kb)
ESM 5 (DOCX 16 kb)


  1. 1.
    O’Leary M, Krailo M, Anderson JR, Reaman GH, Children’s Oncology G (2008) Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin Oncol 35(5):484–493CrossRefGoogle Scholar
  2. 2.
    Phillips SM, Padgett LS, Leisenring WM, Stratton KK, Bishop K, Krull KR, Alfano CM, Gibson TM, de Moor JS, Hartigan DB, Armstrong GT, Robison LL, Rowland JH, Oeffinger KC, Mariotto AB (2015) Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomark Prev 24(4):653–663CrossRefGoogle Scholar
  3. 3.
    Jones DP, Spunt SL, Green D, Springate JE, Children’s Oncology G (2008) Renal late effects in patients treated for cancer in childhood: a report from the Children’s Oncology Group. Pediatr Blood Cancer 51(6):724–731CrossRefGoogle Scholar
  4. 4.
    Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45(18):3213–3219CrossRefGoogle Scholar
  5. 5.
    Fujieda M, Matsunaga A, Hayashi A, Tauchi H, Chayama K, Sekine T (2009) Children’s toxicology from bench to bed—drug-induced renal injury (2): nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci 34(Suppl 2):Sp251–Sp257PubMedGoogle Scholar
  6. 6.
    Goren MP, Wright RK, Horowitz ME (1986) Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 18(1):69–73CrossRefGoogle Scholar
  7. 7.
    Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 82(10):1636–1645CrossRefGoogle Scholar
  8. 8.
    Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bokenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW (2013) Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 10(10):CD008944Google Scholar
  9. 9.
    Sterling M, Al-Ismaili Z, McMahon KR, Piccioni M, Pizzi M, Mottes T, Lands LC, Abish S, Fleming AJ, Bennett MR, Palijan A, Devarajan P, Goldstein SL, O'Brien MM, Zappitelli M (2017) Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. Pediatr Blood Cancer 64(10). CrossRefGoogle Scholar
  10. 10.
    Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629–637CrossRefGoogle Scholar
  11. 11.
    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury (2012). Kidney Int, Suppl 2 (1):1–138Google Scholar
  12. 12.
    Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. (2010) National Institutes of Health. National Cancer Institute. Accessed 29 Aug 2017
  13. 13.
    McCune JS, Friedman DL, Schuetze S, Blough D, Magbulos M, Hawkins DS (2004) Influence of age upon Ifosfamide-induced nephrotoxicity. Pediatr Blood Cancer 42(5):427–432CrossRefGoogle Scholar
  14. 14.
    CDC Growth Charts. (2000) Centers for Disease Control and Prevention/ National Center for Health Statistics. Accessed 29 Aug 2017
  15. 15.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents (2004). Pediatrics 114 (Supplement 2):555–576Google Scholar
  16. 16.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150CrossRefGoogle Scholar
  17. 17.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefGoogle Scholar
  18. 18.
    Flynn JT, Daniels SR, Hayman LL, Maahs DM, BW MC, Mitsnefes M, Zachariah JP, Urbina EM, American Heart Association Atherosclerosis H, Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young (2014) Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension 63(5):1116–1135CrossRefGoogle Scholar
  19. 19.
    O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, European Society of Hypertension Working Group on Blood Pressure M (2003) European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21(5):821–848CrossRefGoogle Scholar
  20. 20.
    Wilson DK, Sica DA, Miller SB (1999) Ambulatory blood pressure nondipping status in salt-sensitive and salt-resistant black adolescents. Am J Hypertens 12(2 Pt 1):159–165CrossRefGoogle Scholar
  21. 21.
    Pickering T (1996) Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 9(1):1–11CrossRefGoogle Scholar
  22. 22.
    Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ (2005) Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111(5):697–716CrossRefGoogle Scholar
  23. 23.
    Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallee M, Ramesh Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Brian Penner S, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Gregoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Poirier L, Padwal RS (2015) The 2015 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 31(5):549–568CrossRefGoogle Scholar
  24. 24.
    Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N (2005) High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44(3):215–219CrossRefGoogle Scholar
  25. 25.
    Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-van Meeteren AY, Bouts AH, Lieverst JA, Bökenkamp A, Koning CCE, Oldenburger F, Wilde JCH, van Leeuwen FE, Caron HN, Kremer LC (2012) Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7(9):1416–1427CrossRefGoogle Scholar
  26. 26.
    Stefanowicz J, Owczuk R, Sierota D, Kaczorowska-Hac B, Balcerska A (2009) Does antineoplasm treatment decrease the glomerular filtration rate in children? Kidney Blood Press Res 32(3):194–199CrossRefGoogle Scholar
  27. 27.
    Skinner R (2018) Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatr Nephrol 33(2):215–225CrossRefGoogle Scholar
  28. 28.
    Elli M, Sungur M, Genc G, Ayyildiz P, Dagdemir A, Pinarli FG, Acar S (2013) The late effects of anticancer therapy after childhood Wilm’s tumor: the role of diastolic function and ambulatory blood pressure monitoring. Jpn J Clin Oncol 43(10):1004–1011CrossRefGoogle Scholar
  29. 29.
    Paradis G, Tremblay MS, Janssen I, Chiolero A, Bushnik T (2010) Blood pressure in Canadian children and adolescents. Health Rep 21(2):15–22PubMedGoogle Scholar
  30. 30.
    Zappitelli M, Joseph L, Gupta IR, Bell L, Paradis G (2007) Validation of child serum creatinine-based prediction equations for glomerular filtration rate. Pediatr Nephrol 22(2):272–281CrossRefGoogle Scholar

Copyright information

© IPNA 2018

Authors and Affiliations

  • Kelly R. McMahon
    • 1
    • 2
  • Maya Harel-Sterling
    • 3
  • Michael Pizzi
    • 1
  • Louis Huynh
    • 4
  • Erin Hessey
    • 5
  • Michael Zappitelli
    • 6
    • 7
    Email author
  1. 1.Department of Pediatrics, Division of Nephrology, Montreal Children’s HospitalMcGill University Health CentreMontrealCanada
  2. 2.Faculty of Medicine, Division of Experimental MedicineMcGill UniversityMontrealCanada
  3. 3.Department of Pediatrics, Toronto Hospital for Sick ChildrenUniversity of TorontoTorontoCanada
  4. 4.Faculty of Health SciencesQueen’s UniversityKingstonCanada
  5. 5.Faculty of Medicine & DentistryUniversity of AlbertaEdmontonCanada
  6. 6.Department of Pediatrics, Division of Nephrology, Toronto Hospital for Sick ChildrenUniversity of TorontoTorontoCanada
  7. 7.Toronto Hospital for Sick ChildrenPeter Gilgan Centre For Research and Learning (PGCRL)TorontoCanada

Personalised recommendations